Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer

European Urology

Volumn 61, Issue 3, 2012, Pages 455-466

  Guazzoni, Giorgio ^a   Lazzeri, Massimo ^a   Nava, Luciano ^b   Lughezzani, Giovanni ^a   Larcher, Alessandro ^a   Scattoni, Vincenzo ^a   Gadda, Giulio Maria ^a   Bini, Vittorio ^c   Cestari, Andrea ^a   Buffi, Nicol Maria ^a   Freschi, Massimo ^a   Rigatti, Patrizio ^a   Montorsi, Francesco ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b Department of Urology   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

2 proPSA; Pathologic examination; Predictive models; Prostate cancer; Prostate health index; Prostate specific antigen; Radical prostatectomy

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PATIENT; DIAGNOSTIC ACCURACY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; SERUM;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84856374086     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.10.038     Document Type: Article

References (21)

1. M. Lazzeri, and G. Guazzoni Focal therapy meets prostate cancer Lancet 376 2010 1036 1037
2. G. Lughezzani, A. Briganti, and P.I. Karakiewicz Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature Eur Urol 58 2010 687 700
3. D. Quinn, and M. Gross Show us a sign: the search for "game changing" prostate cancer biomarkers Lancet Oncol 12 2011 204 206
4. C. Stephan, A.M. Kahrs, and H. Cammann A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases Prostate 69 2009 198 207
5. L.J. Sokoll, M.G. Sanda, and Z. Feng A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness Cancer Epidemiol Biomarkers Prev 19 2010 1193 1200
6. B.V. Le, C.R. Griffin, and S. Loeb [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study J Urol 183 2010 1355 1359
7. F.H. Jansen, R.H.N. Van Schaik, and J. Kurstjens Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves the diagnostic accuracy in prostate cancer detection Eur Urol 57 2010 921 927
8. G. Guazzoni, L. Nava, and M. Lazzeri Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting Eur Urol 60 2011 214 222
9. W.J. Catalona, A.W. Partin, and M.G. Sanda A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range J Urol 185 2011 1650 1655
10. A. Semjonow, T. Köpke, and E. Eltze Pre-analytical in-vitro stability of [-2]proPSA in blood and serum Clin Biochem 47 2010 926 928
11. T.H. Van der Kwast, M.B. Amin, and A. Billis International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume Mod Pathol 24 2011 16 25
12. J.I. Epstein, W.C. Allsbrook Jr., and M.B. Amin The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Am J Surg Pathol 29 2005 1228 1242 (Pubitemid 41232997)
13. E.R. DeLong, D.M. DeLong, and D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837 845
14. A.J. Vickers, and E.B. Elkin Decision curve analysis: a novel method for evaluating prediction models Med Decis Making 26 2006 565 574 (Pubitemid 44728772)
15. M. Auprich, F.K.-H. Chun, and J.F. Ward Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging Eur Urol 59 2011 96 105
16. H. Nakanishi, J. Groskopf, and H.A. Fritsche PCA3 molecular urine assay correlates with prostate cancer tumour volume: implication in selecting candidates for active surveillance J Urol 179 2008 1804 1809
17. V. Mouraviev, A. Villers, D.G. Bostwick, T.M. Wheeler, R. Montironi, and T.J. Polascik Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy BJU Int 108 2011 1074 1085
18. R. Autorino, G. Di Lorenzo, and R. Damiano Pathology of the prostate in radical cystectomy specimens: a critical review Surg Oncol 18 2009 73 84
19. J.W. Anast, G.L. Andriole, T.A. Bismar, Y. Yan, and P.A. Humphrey Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology 64 2004 544 550 (Pubitemid 39200755)
20. G. Giannarini, C.A. Scott, U. Moro, B. Pertoldi, C.A. Beltrami, and C. Selli Are PSA density and PSA density of the transition zone more accurate than PSA in predicting the pathological stage of clinically localized prostate cancer? Urol Oncol 26 2008 353 360 (Pubitemid 351885368)
21. M.F. O'Brien, A.M. Cronin, and P.A. Fearn Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy J Clin Oncol 27 2009 3591 3597